Version française

Stago at the Heart of Haemostasis

People dedicated to Health

From ideas...to medical applications

Complications of heparin treatment

In the absence of any straightforward laboratory tests, the most severe complication, known as type II heparin-induced thrombocytopenia (HIT) has...

From ideas...to medical applications

STA-Procoag-PPL or making microparticles talk

Midway between plasma haemostasis and cellular haemostasis are microparticles, rich in procoagulant phospholipids. An increase in this procoagulant...

From ideas...to medical applications

Remaining abreast of changes in biomedical science

Listening to and exchanging ideas with members of the biomedical science community has enabled Stago to develop its expertise in the search for...

From ideas...to medical applications

Complete industrial autonomy

Achieving a balanced policy with regard to investment in research & development (R&D), technological monitoring and rational acquisitions is a key...

Events

All news

iPad app

This Ouvre un lien externe dans la fenêtre courantefree educational application in English is the first of its kind and has been developed by an expert in Haemostasis… Stago.

Products & Services

STA®-Liatest® D-Di Plus, Less interferences for even More Confidence

As part of Stago's continuous improvement commitment, STA® -Liatest® D-Di Plus* was developed as an evolution of the STA® -Liatest® D-Di, one of the most published D-Dimer assays, also FDA approved for aid in the diagnosis of Veno...

Stago Catalogue

Did you know?

Heparin was discovered independently in 1911 by Doyon and in 1916 by McLean, for different reasons. The effect of heparin on blood clotting, however, had been observed one-third of a century earlier.

RSS feed | Contact us | Credits and copyrights | Disclaimer | Site map |